BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69db8d5f0b0a3
DTSTAMP:20260412T081735
DTSTART:20170601T150000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20170601T150000
URL:https://murmitoyen.com/events/vanille/udem/detail/766124-advances-towar
 ds-the-local-treatment-of-osteoarthritis-with-nano-and-microconstructs
LOCATION:Université de Montréal - Pavillon Claire-McNicoll\, 2900\, chemi
 n de la Tour\, Montréal\, QC\, Canada\, H3T 1J6
SUMMARY:Advances Towards the Local Treatment of Osteoarthritis with nano- a
 nd microconstructs
DESCRIPTION:Séminaire
\nÉric Allémann (École de pharmacie Genève-Lausa
 nne) est l’invité de la professeure Gaëlle Roullin dans le cadre des s
 éminaires de l’axe « Formulation et analyse du médicament » de la 
 Faculté de pharmacie de l'Université de Montréal.  
\nEric Allémann w
 as born in1963. He studied pharmacy at the University of Geneva. From 1990
  to 1993\, he worked on his thesis in the field of parenteral polymeric dr
 ug delivery systems with extended release properties. He obtained his Ph.D
 . in 1993. He went then to the Faculty of Medicine of the University of Sh
 erbrooke (Quebec) for a post-doc. In 1995\, he became research associate a
 nd lecturer at the University of Geneva. In 1997\, the Swiss Confederation
  for the renewal of academic positions appointed him. He obtained in Octob
 er 1999 a position of “maître d'enseignement et de recherche”. Since 
 October 2001\, he joined the Geneva research center of the pharmaceutical 
 company Bracco Group\, as senior research scientist. He was involved in th
 erapeutic and diagnostic nanomedicines. In 2004\, he was appointed Manager
  and was heading the Department of Novel Agents Research at Bracco Researc
 h Geneva. In 2009 he became full professor of Pharmaceutical technology at
  the Geneva-Lausanne School of Pharmacy (EPGL)\, located at the University
  of Geneva. Since July 2014\, he is Vice-president of the EPGL. Eric Allé
 mann's research interests are focused on the delivery of active substances
  by means of supramolecular constructs\, nano- and microparticles for the 
 controlled release and drug targeting as well as for contrast agents for v
 arious medical imaging techniques.
\nAdditionally to his academic duties\,
  Eric is scientific advisor of Twenty Green and co-founder of Kylys\, two 
 biotech start-up companies located in Switzerland.
\nHe is (co)-inventor f
 or 13 international patents and has authored and co-authored 90 research a
 nd review articles.
\nLien de l'annonce
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR